Join to view full profile
5653 Frist BlvdSuite 434Hermitage, TN 37076
Phone+1 615-871-9996
Fax+1 615-871-9661
Dr. Blakely is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2001 - 2004
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1999 - 2001
University of Tennessee College of Medicine (Memphis)Internship, Internal Medicine, 1998 - 1999
University of Tennessee Health Science Center College of MedicineClass of 1998
Certifications & Licensure
TN State Medical License 2004 - 2028
AR State Medical License 2004 - 2011
TX State Medical License 2001 - 2007
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2012, 2014-2017
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2009-2012
Clinical Trials
- Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
Publications & Presentations
PubMed
- 4 citationsImpact of clinical pathways on treatment patterns and outcomes for patients with non-small-cell lung cancer: real-world evidence from a community oncology practice.Natalie R Dickson, Karen D Beauchamp, Toni S Perry, Ashley Roush, Deborah Goldschmidt
Journal of Comparative Effectiveness Research. 2022-06-01 - 7 citationsA Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast CancerDenise A. Yardley, William Liggett, Mark Mainwaring, Aurelio Castrellon, Laura Blakely
Clinical Breast Cancer. 2020-04-01 - 6 citationsRegorafenib Prior to Selective Internal Radiation Therapy Using 90Y-Resin Microspheres for Refractory Metastatic Colorectal Cancer Liver Metastases: Analysis of Safety...Andrew S. Kennedy, Dianna Shipley, Max Shpak, Laura Blakely, Brian Hemphill
Frontiers in Oncology. 2019-07-10
Press Mentions
Oncologist Warns That Medicare’s Drug Price Negotiations Could Be “Catastrophic”July 17th, 2026
Oncology Leaders in the Spotlight: Rapid Roundup for May and June 2026July 10th, 2026
First-Of-Its-Kind Report Answers Big Question in Community OncologyMay 6th, 2026
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:










